Navigation Links
Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
Date:5/7/2012

NEW YORK, May 7, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease, today announced that a conference call will be held on Wednesday, May 9, 2012 at 8:30 a.m. EDT to discuss results for the first quarter ended March 31, 2012 and a business outlook for the remainder of 2012. Ron Bentsur, Chief Executive Officer of Keryx, will host the call.

In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

Keryx will announce its financial results for this period in a press release to be issued prior to the call.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City.

KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com

 


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014  CytRx Corporation (Nasdaq: CYTR ), ... today announced that David J. Haen , Vice ... in the Biotech Industry Conference on Friday, September 26 th ... take place at the Millennium Broadway Hotel in ... live and archived webcast of the presentation will be ...
(Date:9/19/2014)... PHILADELPHIA , Sept. 19, 2014  PCI ... Services International (Biotec).  Biotec is a leading provider ... Services headquartered in Bridgend, Wales ... .  The addition significantly expands PCI,s presence in ... medicinal products by adding packaging, storage and distribution ...
(Date:9/18/2014)... Sept. 18, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... focused on licensing, developing and commercializing innovative biopharmaceutical ... exercise of the underwriters, option to purchase 675,000 ... the company,s previously announced public offering of 4,500,000 ... are being offered by Aratana Therapeutics.  With the ...
Breaking Medicine Technology:CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 2
... U.S. Food and Drug Administration (FDA) approved ... of INTELENCE ® (etravirine), a non-nucleoside reverse transcriptase ... virus (HIV-1) in treatment-experienced adults with resistance to an ... The recommended oral dose of INTELENCE tablets is 200 ...
... KONG, Jan. 3, 2011 /PRNewswire-Asia-FirstCall/ -- Golden Meditech ... with its subsidiary collectively as the "Group" - 801.HK), ... announce that the Company has obtained the approvals from ... Futures Bureau for its proposed offering and listing of ...
Cached Medicine Technology:FDA Approves New Dosage Strength for INTELENCE® 2FDA Approves New Dosage Strength for INTELENCE® 3FDA Approves New Dosage Strength for INTELENCE® 4FDA Approves New Dosage Strength for INTELENCE® 5Golden Meditech as First Chinese Healthcare Enterprise to Obtain Approval for Taiwan Depositary Receipts Offering 2
(Date:9/19/2014)... September 19, 2014 The Alliance ... partnership with the National Fire Protection Association (NFPA), ... collaboration, formalized today in a Memorandum of Understanding ... factories, workers and other stakeholders with information, guidance ... protect the health and safety of workers in ...
(Date:9/19/2014)... 2014 "I have difficulty putting in ... to stretching the skin around my eyes during the ... me to design a more convenient method of performing ... provides a quicker, easier, more sanitary method of putting ... this task manually, saves time and effort, and helps ...
(Date:9/19/2014)... approaches to reducing poverty that help children and ... advocates, and foundations. By combining education and training ... jobs that offer a path out of poverty ... these programs aim to improve the life opportunities ... report from the National Center for Children in ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- When it comes ... in the United States, while the District of Columbia ... the past decade, deaths from gun-related violence -- including ... the United States, the study revealed. Hawaii,s rate was ... of the spectrum, the District of Columbia had the ...
(Date:9/19/2014)... collaborative research team led by Medical College of Wisconsin (MCW) ... and insulin levels in rats, mice and in humans. The ... Genetics . , Leah Solberg Woods, Ph.D., associate ... Children,s Hospital of Wisconsin Research Institute, led the study and ... of the paper identified a gene called Tpcn2 in which ...
Breaking Medicine News(10 mins):Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 3Health News:A two generation lens: Current state policies fail to support families with young children 2Health News:U.S. Gun Deaths Lowest in Hawaii, Highest in D.C. 2
... Dietary Guidelines (i.e., men who usually drink more than two ... one drink per day) or those who binge drink are ... new study accepted for publication in The Endocrine Society,s ... metabolic syndrome consists of a series of risk factors and ...
... Shows Overuse of Technology Is Wreaking ... Havoc on Romance -, ... juggling lengthy to-do lists, jam-packed schedules, and the 24/7,demands of children and ... wired lifestyle allows people to stay,connected with more friends, family and co-workers ...
... following news tips are based on poster and oral presentations ... in Chicago from July 26 to July 31. Each presentation ... Brain Atrophy and Biomarkers May Help Identify People at Risk ... Department of Psychiatry, NYU Langone Medical Center , EMBARGOED FOR ...
... VNUS(R) Medical,Technologies, Inc. (Nasdaq: VNUS ) updates and corrects ... 2008 net income is expected to,range from approximately $13.1 million ... which is changed from the previously announced net,income of $11.5 ... per,share., ABOUT VNUS MEDICAL TECHNOLOGIES, INC., VNUS is ...
... and Charitable Care and Coverage, OAKLAND, Calif., ... has approved more than 415 community benefit grants ... quarter of 2008.,The quarter,s contributions continue to support ... measurable impact on the health of,its communities., ...
... PORTLAND, Ore., July 29 Sometimes the simplest ... to health care --,are the most difficult., Regence ... company has launched a Web site that enables consumers ... health-related topics., The video cards are part of ...
Cached Medicine News:Health News:Drinking in excess associated with increased risk for metabolic syndrome 2Health News:Gold Medalist Jennie Finch & Relationship Expert Stacy Kaiser Help 'Wired' Couples Unplug 2Health News:Gold Medalist Jennie Finch & Relationship Expert Stacy Kaiser Help 'Wired' Couples Unplug 3Health News:Gold Medalist Jennie Finch & Relationship Expert Stacy Kaiser Help 'Wired' Couples Unplug 4Health News:New Alzheimer's predictors advance earlier detection 2Health News:New Alzheimer's predictors advance earlier detection 3Health News:New Alzheimer's predictors advance earlier detection 4Health News:New Alzheimer's predictors advance earlier detection 5Health News:New Alzheimer's predictors advance earlier detection 6Health News:New Alzheimer's predictors advance earlier detection 7Health News:New Alzheimer's predictors advance earlier detection 8Health News:VNUS Revises Upward Full-Year 2008 Net Income Guidance 2Health News:Kaiser Permanente Approves $22 Million in Community Benefit Grants in Second Quarter of 2008 2Health News:Kaiser Permanente Approves $22 Million in Community Benefit Grants in Second Quarter of 2008 3Health News:Regence Video Cards Help Start Important Health Conversations With Friends, Family 2
... was the first device ... after diagnostic and interventional ... It is a collagen-based ... for immediate sheath removal ...
... VasoSeal VHD was ... rapidly stop bleeding after ... and radiology procedures. It ... sealing device approved for ...
InterVascular HemaPatch product line offers the vascular surgeon a range of collagen coated patches in a range of larger sizes angioplasty, or profundaplasty procedures without suture hole bleeding. ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
Medicine Products: